Tirzepatide: Dual GIP/GLP-1 Agonism and the New Standard in Metabolic Research

Tirzepatide is a 39-amino acid peptide based on the native GIP sequence, with modifications to enable GLP-1R activity and a C20 fatty diacid modification for albumin binding and once-weekly dosing. Its receptor binding profile is asymmetric: it is a full agonist at GIPR and a partial agonist at GLP-1R, with approximately 5-fold selectivity for GIPR over GLP-1R.

This asymmetric agonism is pharmacologically significant. At GLP-1R, tirzepatide produces submaximal receptor activation relative to semaglutide, yet achieves superior clinical outcomes — suggesting that GIPR co-agonism provides additive or synergistic effects that compensate for the reduced GLP-1R efficacy. The mechanism of this synergy remains an active area of research.

The SURPASS program comprised five Phase 3 trials evaluating tirzepatide in type 2 diabetes. SURPASS-2 (Frias et al., 2021) compared tirzepatide (5, 10, 15 mg) to semaglutide 1 mg in 1,879 patients with T2DM inadequately controlled on metformin. At 40 weeks, tirzepatide 15 mg reduced HbA1c by 2.46% vs. 1.86% for semaglutide, and produced 12.4 kg weight loss vs. 6.2 kg — both statistically superior outcomes.

SURPASS-4 demonstrated cardiovascular safety in high-risk T2DM patients, and SURPASS-5 showed efficacy as add-on to insulin glargine. The consistent superiority of tirzepatide over semaglutide across the SURPASS program established dual GIP/GLP-1 agonism as the new standard of care for T2DM pharmacotherapy.

SURMOUNT-1 (Jastreboff et al., 2022) enrolled 2,539 adults with obesity (BMI ≥30 or ≥27 with comorbidity) without diabetes and randomized them to tirzepatide (5, 10, 15 mg) or placebo for 72 weeks. At the 15 mg dose, participants lost a mean of 22.5% of body weight — a result that had previously only been achieved with bariatric surgery.

Importantly, 37% of participants on tirzepatide 15 mg achieved ≥25% weight loss, and 55% achieved ≥20% weight loss. These response rates far exceed those of prior GLP-1R monotherapy trials, providing strong clinical validation for the additive contribution of GIPR agonism to weight loss outcomes.

The role of GIPR in weight regulation was paradoxical prior to tirzepatide's clinical success. Early data suggested that GIPR antagonism (not agonism) reduced body weight in rodents, leading to uncertainty about whether GIPR agonism would be beneficial or detrimental for obesity treatment.

Tirzepatide's clinical data resolved this paradox by demonstrating that GIPR agonism in the context of GLP-1R co-activation produces robust weight loss. Mechanistic studies suggest that GIPR agonism in the central nervous system (hypothalamus and brainstem) reduces the nausea associated with GLP-1R agonism, enabling higher effective doses and greater appetite suppression. GIPR agonism in adipose tissue also promotes lipolysis and may reduce lipotoxicity.